INCOG BioPharma Services Builds State-of-the-Art Facility With Promise to Deliver a Better Customer Experience


INCOG BioPharma Services is nearing completion on the construction of its manufacturing facility and global headquarters in Fishers, Indiana.

The 90,000-sq-ft facility will be the epicenter of INCOG’s manufacturing operations that will support biopharmaceutical companies in advancing and accelerating early phase clinical projects, while also providing commercial scale manufacturing in support of global product launches and routine commercial supply.

Alex Haig, Vice President of Operations at INCOG, said “This entire facility has been designed to meet or exceed best-in-class industry standards. From our turn-key cleanrooms, designed and installed by AES Cleanroom Technology, to our best-in-class multi-use filling equipment from Optima Pharma, this site enables us to accelerate and scale operations for our customers to supply biopharmaceutical products to patients across vial, syringe and cartridge manufacturing platforms.”

Alongside the new building’s state-of-the-art equipment and a talented technical team, the company is looking to reinvigorate the CDMO customer experience with its approach to customer service. INCOG was conceived from the simple idea that there is a better way of working in the CDMO industry that puts excellent customer service front and center.

INCOG’s CEO, President and Founder, Cory Lewis, explains “Having worked in the CDMO space for more than 20 years, I’ve seen many companies focused solely on throughput, equipment and processes and less on customer care. At INCOG, we wanted to take the lessons that we have learned in the industry and create something better. We aim to maximize quality and operations while offering a best-in-class customer service experience at each touchpoint in the development, manufacturing, and supply chain process. Through fostering a culture of collaboration, honesty, trust, and transparency with our customers and employees, we will set a new standard in the CDMO space that puts customer care as the top priority.”

As the facility construction nears completion, INCOG is actively onboarding new customers. The company will be offering development, analytical testing, stability studies and storage, and cold chain storage starting in H1-2022 and will be fully operational and begin offering CGMP manufacturing in Q3-2022 after completing a robust qualification process and media fill campaign.

To support its growth, INCOG purchased the 16-acre site in December 2020, and 12-months to the day they celebrated occupancy of the office space at their newly constructed site.  INCOG plans to create more than 150 jobs by the end of 2024.

If you are interested in joining a team that puts employees and customer service first, please visit www.incogbiopharma.com/careers to learn about open positions or email at careers@incogbiopharma.com.

If you need support on a project, please contact INCOG’s business development team at info@incogbiopharma.com, or for more information on INCOG BioPharma Services, visit www.incogbiopharma.com.

INCOG has been designed and built from decades of experience with a clear purpose: to deliver better CDMO services in the injectable drug product space. With our dedicated team, best-in-class processes, and state-of-the-art equipment, we deliver meaningful results and stand-out customer experiences. We are here to strive for the best – for our team and for our customers. We are in it with you from the moment we start work on your project. We go above and beyond to understand your requirements, meet your needs, and foster a truly collaborative partnership.

Founded in June 2020, INCOG BioPharma Services offers development and manufacturing services to both early phase and late phase biopharmaceutical companies.  The company’s service offering includes filling drug product into vials, syringes, and cartridges. INCOG also offers support services to include formulation development, analytical development, stability testing and storage, and final inspection, labelling, packaging, and device assembly.